Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Melanoma-intrinsic β-catenin Signalling Prevents Anti-tumour Immunity
Stefani Spranger, R. Bao, T. Gajewski
Published 2015 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Melanoma treatment is being revolutionized by the development of effective immunotherapeutic approaches. These strategies include blockade of immune-inhibitory receptors on activated T cells; for example, using monoclonal antibodies against CTLA-4, PD-1, and PD-L1 (refs 3, 4, 5). However, only a subset of patients responds to these treatments, and data suggest that therapeutic benefit is preferentially achieved in patients with a pre-existing T-cell response against their tumour, as evidenced by a baseline CD8+ T-cell infiltration within the tumour microenvironment. Understanding the molecular mechanisms that underlie the presence or absence of a spontaneous anti-tumour T-cell response in subsets of cases, therefore, should enable the development of therapeutic solutions for patients lacking a T-cell infiltrate. Here we identify a melanoma-cell-intrinsic oncogenic pathway that contributes to a lack of T-cell infiltration in melanoma. Molecular analysis of human metastatic melanoma samples revealed a correlation between activation of the WNT/β-catenin signalling pathway and absence of a T-cell gene expression signature. Using autochthonous mouse melanoma models we identified the mechanism by which tumour-intrinsic active β-catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy. Specific oncogenic signals, therefore, can mediate cancer immune evasion and resistance to immunotherapies, pointing to new candidate targets for immune potentiation.
This paper references
CCR5 provides a signal for microbial induced production of IL-12 by CD8α+ dendritic cells
J. Aliberti (2000)
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
J. Landsberg (2012)
Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting
H. Matsushita (2012)
Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.
Gulsun Erdag (2012)
Generation of Th1-Polarizing Dendritic Cells Using the TLR7/8 Agonist CL075
Stefani Spranger (2010)
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.
W. Peng (2012)
Immune Suppression and Resistance Mediated by Constitutive Activation of Wnt/β-Catenin Signaling in Human Melanoma Cells
T. Yaguchi (2012)
BRafV600E cooperates with Pten silencing to elicit metastatic melanoma
D. Dankort (2009)
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Bo Li (2011)
β-Catenin Inhibits T Cell Activation by Selective Interference with Linker for Activation of T Cells–Phospholipase C-γ1 Phosphorylation
Gregory Driessens (2011)
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
K. Wang (2010)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger (2013)
An integrated map of genetic variation from 1,092 human genomes
M. V. García (2012)
Flt3L-dependence helps define an uncharacterized subset of murine cutaneous dendritic cells
Shamim A. Mollah (2014)
Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells
S. Bedoui (2009)
Pten 2/2 /CAT-STA mice. a, Distribution of T-cell subsets in Braf V600E /Pten 2/2 and Braf V600E /Pten 2/2 /CAT-STA tumours
β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.
W. Damsky (2011)
Cancer immunotherapy comes of age
I. Mellman (2011)
STRING 8—a global view on proteins and their functional interactions in 630 organisms
L. Jensen (2009)
An immune-active tumor microenvironment favors clinical response to ipilimumab
R. Ji (2011)
Activating transcription factor 3 (ATF3) represses the expression of CCL4 in murine macrophages.
Ciera Khuu (2007)
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Seng-Ryong Woo (2012)
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
Characterization of melanocyte‐specific inducible Cre recombinase transgenic mice
M. Bosenberg (2006)
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
S. Topalian (2014)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
Stefani Spranger (2014)
Stabilization of β-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia
F. Gounari (2002)
Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity
K. Hildner (2008)
Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
T. C. Manning (1997)
Hedgehog signaling in the neural crest cells regulates the patterning and growth of facial primordia.
Juhee Jeong (2004)
Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma.
D. Rimm (1999)
Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens
Sarah L. Jongbloed (2010)
naive (CD62L 1 CD44 2 ) and effector (CD62L 2 CD44 1 ) T cells (pre-gated on CD3 1 CD8 1 T cells), and one representative example of CD44/CD45RA staining (c)
Extended Data Figure 4 | Characterization of the T-cell infiltrate in
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?
A. Cipponi (2011)
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
H. L. Kaufman (2013)
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells
M. Fuertes (2011)
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.
H. Harlin (2009)
Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer.
A. Cheung (2008)
N-myc Downstream-regulated Gene 2, a Novel Estrogen-targeted Gene, Is Involved in the Regulation of Na+/K+-ATPase*
Y. Li (2011)
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
J. Galon (2006)
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.
D. Dankort (2007)
Analyzing real-time PCR data by the comparative CT method
Thomas D. Schmittgen (2008)
Quantification and comparison of PD-1/Lag3 double-positive T cells in Braf V600E /Pten 2/2 and Braf V600E /Pten 2/2 /CAT-STA tumours
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice
A. Suzuki (1998)
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
M. Wilkerson (2010)
This paper is referenced by
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade
Ilaria Penna (2016)
Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications
Jessica Roelands (2017)
Dendritic Cells: The Tools for Cancer Treatment
Hanne Locy (2018)
Current condition and issues of animal evaluation models for cancer immunotherapy.
Motoya Mie (2016)
PD-1/PD-L1 antagonists in gastric cancer: Current studies and perspectives
Jian Li (2019)
The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
S. Palakurthi (2019)
Signaling Pathways Associated with Cancer Stem Cells Play a Significant Role in Immunotherapy Resistance
Y. Zhu (2019)
Wnt3a/β-Catenin Signaling Conditions Differentiation of Partially Exhausted T-effector Cells in Human Cancers
V. Schinzari (2018)
Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.
Y. Chae (2018)
A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy
Y. Fujiwara (2020)
β-Catenin-driven adrenocortical carcinoma is characterized with immune exclusion
S. Liu (2018)
Regulation of the Inflamed Tumor Phenotype in Melanoma Immunotherapy
Jennifer A. Lo (2016)
Major fundamental factors hindering immune system in defense against tumor cells; the link between insufficiency of innate immune responses, metabolism, and neurotransmitters with effector immune cells disability.
Saman Bahrambeigi (2019)
Impact of oncogenic pathways on evasion of antitumour immune responses
Stefani Spranger (2018)
Obstacles to T cell migration in the tumor microenvironment.
Alba Nicolás-Boluda (2019)
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.
B. Mlecnik (2016)
Conditional activation of immune-related signatures and prognostic significance: a pan-cancer analysis
Jessica Roelands (2019)
The WNT/β-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro
Dmitry Stakheev (2019)
Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga.
Irene Catalano (2019)
Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy
Marcin Komorowski (2016)
Antigen Presentation in Transplantation.
M. Alegre (2016)
Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
S. Ganesh (2016)
β-Catenin–mediated immune evasion pathway frequently operates in primary cutaneous melanomas
J. Nsengimana (2018)
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
B. Homet Moreno (2016)
Wnt/β-catenin activation and macrophage induction during liver cancer development following steatosis
A. Debebe (2017)
CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell–Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1
Y. Lee (2016)
Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes
Yangzhi Qi (2020)
Acquired Resistance to Immune Checkpoint Inhibitors.
A. Schoenfeld (2020)
Mechanisms of Resistance to PD-1 Checkpoint Blockade
Justin C. Moser (2020)
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
A. Kamphorst (2017)
Tailoring precision immunotherapy: coming to a clinic soon?
S. Han (2020)
Implication des cellules myéloïdes immunosuppressives (MDSC) et des lymphocytes TH17 dans l’efficacité des chimiothérapies et de l’immunothérapie
E. Limagne (2017)See more